Hudson Bay Capital Management
TGTX icon

Hudson Bay Capital Management’s TG Therapeutics TGTX Stock Holding History

Hudson Bay Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,590
Closed -$684K – 1691
2026
Q1 		$684K Buy
+20,590
New +$614K ﹤0.01% 939
2024
Q3 		– Sell
-147,100
Closed -$2.62M – 1045
2024
Q2 		$2.62M Buy
+147,100
New +$2.35M 0.01% 495

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Hudson Bay Capital Management's TGTX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 20,590 shares — an estimated $684K sold.

Hudson Bay Capital Management first reported a position in TGTX in Q2 2024 and held it in 2 quarters. The position peaked at $2.62M in Q2 2024. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 20,590 TG Therapeutics shares in Q2 2026, an estimated $684K.
  • Hudson Bay Capital Management first reported a position in TG Therapeutics in Q2 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's TG Therapeutics position peaked at $2.62M in Q2 2024.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.